A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 2

Conditions

Ovarian Neoplasms

Treatments

Drug: Carboplatin

Drug: Pegylated Liposomal Doxorubicin

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00780039

P03625

Details and patient eligibility

About

Doxorubicin has been used to treat ovarian cancer as part of different combination therapies, but high cumulative doses should be avoided because of the risk of cardiotoxicity. Pegylated Liposomal Doxorubicin (Caelyx) has been developed to reduce the risk of cardiotoxicity. The purpose of this study is to evaluate the safety and efficacy of Caelyx in combination with carboplatin in women with recurrent ovarian cancer.

Enrollment

58 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age >=18 years old
Subject must have histological diagnosis of epithelial ovarian cancer
Subject must have received a taxane and platinum regimen and have maintained a treatment-free status for at least six months and not more than twelve months following completion of first line therapy.
Subject must have measurable ovarian cancer by appropriate radiological imaging.
ECOG performance Score of 0 or 1.
Subject's life expectancy must be > 6 months.
Subject must have normal organ function, except if abnormal due to tumor involvement:
- Adequate bone marrow function (platelets >=100 X 10^9/L, hemoglobin >=100 g/L, neutrophils >=1.5 X 10^9/L)
- Adequate renal function (serum creatinine<=1.5 X the upper limit of normal (ULN)
- Adequate liver function (bilirubin and AST or ALT<=2 times ULN, unless related to primary disease.
MUGA scan must indicate left ventricular ejection fraction above 90%.
Women of childbearing potential must be using adequate contraception (prescribed under medical supervision) and have a negative pregnancy test at the time of enrollment.
Subject must be able to sign written informed consent.

Exclusion criteria

Subject who is pregnant or is breast feeding.
Subject who has history of cardiac disease, with New York Heart Association Class II or greater.
Subject with a history of severe hypersensitivity reactions to products containing Cremophor® EL.
Subject with clinically significant hepatic disease.
Subject who has uncontrolled bacterial, viral, or fungal infection.
Subject who exhibits confusion or disorientation.
Subject with any condition that would prevent adequate follow-up.
Subject with a history of prior malignancy treated with systemic chemotherapy or radiotherapy.
Subject who has received two or more prior chemotherapy regimens for ovarian cancer.